Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 10/20 | 0.63 |
| ▸ | HTR3E | A5X5Y0 | 6/20 | 0.63 |
| ▸ | HTR3B | O95264 | 6/20 | 0.63 |
| ▸ | HTR3A | P46098 | 6/20 | 0.63 |
| ▸ | HTR3D | Q70Z44 | 6/20 | 0.63 |
| ▸ | HTR3C | Q8WXA8 | 6/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.59 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7059721 | 0.95 | CHRNA7 (0.69) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7061849 | 0.84 | CHRNA7 (0.56) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6492493 | 0.79 | CHRNA7 (0.59) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4198172 | 0.78 | ALDH1A1 (0.72) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4202120 | 0.78 | ALDH1A1 (0.72) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7059178 | 0.76 | CHRNB2 (0.63) | CHRNA7NPC1RAB9AS1PR1USP30 | |
| SCHEMBL6099406 | 0.76 | CHRNA7 (0.58) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL17933816 | 0.75 | NPC1 (0.95) | NPC1RAB9AS1PR1 | |
| SCHEMBL7123351 | 0.75 | CHRNA7 (0.63) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6496769 | 0.75 | USP30 (0.55) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | MALT1, WFS1, NR5A1 | CHRNA7 1097/4885HTR3E 3516/4885HTR3B 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.